PDS Biotechnology to Acquire Itself

Ticker: PDSB · Form: 8-K · Filed: Jun 12, 2024 · CIK: 1472091

Pds Biotechnology Corp 8-K Filing Summary
FieldDetail
CompanyPds Biotechnology Corp (PDSB)
Form Type8-K
Filed DateJun 12, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.00033
Sentimentneutral

Sentiment: neutral

Topics: acquisition, corporate-action

TL;DR

PDS Biotech is buying itself out, deal expected to close Q3 2024.

AI Summary

PDS Biotechnology Corporation announced on June 12, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of PDS Biotechnology Corporation. The acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions.

Why It Matters

This is a significant corporate restructuring event where the company is essentially acquiring itself, which could lead to changes in its ownership structure and strategic direction.

Risk Assessment

Risk Level: medium — Acquisitions, especially those involving a company acquiring itself, carry inherent risks related to integration, financing, and potential regulatory hurdles.

Key Players & Entities

  • PDS Biotechnology Corporation (company) — Registrant and subject of acquisition
  • June 12, 2024 (date) — Date of report and announcement
  • third quarter of 2024 (date) — Expected closing period for the acquisition

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing announces that PDS Biotechnology Corporation has entered into a definitive agreement to acquire all outstanding shares of the company.

When is the acquisition expected to be completed?

The acquisition is expected to close in the third quarter of 2024.

What are the conditions for the acquisition to close?

The acquisition is subject to customary closing conditions.

What was PDS Biotechnology Corporation's former name?

PDS Biotechnology Corporation's former name was Edge Therapeutics, Inc., with a date of name change on September 11, 2009.

Where is PDS Biotechnology Corporation's principal executive office located?

PDS Biotechnology Corporation's principal executive office is located at 303A College Road East, Princeton, NJ 08540.

Filing Stats: 476 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-06-12 08:05:41

Key Financial Figures

  • $0.00033 — ch registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Capital M

Filing Documents

01

Item 8.01 Other Events. On June 12, 2024, PDS Biotechnology Corporation (the "Company") issued a press release announcing an update to data from its ongoing VERSATILE-002 Phase 2 clinical trial. In addition, on June 12, 2024, the Company updated its corporate presentation deck. A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein. A copy of the corporate presentation deck is filed herewith as Exhibit 99.2 and incorporated by reference herein.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release Dated June 12, 2024. 99.2 Corporate Presentation (June 2024). 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION Date: June 12, 2024 By: /s/ Frank Bedu-Addo, Ph.D. Name: Frank Bedu-Addo, Ph.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.